These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
94 related articles for article (PubMed ID: 1527407)
1. A phase I study of ampligen in human immunodeficiency virus-infected subjects. Armstrong JA; McMahon D; Huang XL; Pazin GJ; Gupta P; Rinaldo CR; Schoenfeld DA; Gaccione P; Tripoli CA; Bensasi S J Infect Dis; 1992 Oct; 166(4):717-22. PubMed ID: 1527407 [TBL] [Abstract][Full Text] [Related]
2. Results of a double-blind placebo-controlled study of the double-stranded RNA drug polyI:polyC12U in the treatment of HIV infection. Thompson KA; Strayer DR; Salvato PD; Thompson CE; Klimas N; Molavi A; Hamill AK; Zheng Z; Ventura D; Carter WA Eur J Clin Microbiol Infect Dis; 1996 Jul; 15(7):580-7. PubMed ID: 8874076 [TBL] [Abstract][Full Text] [Related]
4. Synergistic inhibition of AZT-resistant HIV by AZT combined with poly(I):poly(C12U), without synergistic toxicity to bone marrow progenitor cell elements. Gillespie D; Hubbell HR; Carter WA; Midgette P; Elsasser W; Mullaney R; Strayer DR In Vivo; 1994; 8(3):375-81. PubMed ID: 7803722 [TBL] [Abstract][Full Text] [Related]
5. A pilot study of low-dose zidovudine in human immunodeficiency virus infection. Collier AC; Bozzette S; Coombs RW; Causey DM; Schoenfeld DA; Spector SA; Pettinelli CB; Davies G; Richman DD; Leedom JM N Engl J Med; 1990 Oct; 323(15):1015-21. PubMed ID: 1977080 [TBL] [Abstract][Full Text] [Related]
6. Mismatched double-stranded RNA, Ampligen (poly(I): poly(C12U), demonstrates antiviral and immunostimulatory activities in HIV disease. Carter WA; Ventura D; Shapiro DE; Strayer DR; Gillespie DH; Hubbell HR Int J Immunopharmacol; 1991; 13 Suppl 1():69-76. PubMed ID: 1688087 [TBL] [Abstract][Full Text] [Related]
7. Didanosine therapy in patients intolerant of or failing zidovudine therapy. Rathbun RC; Martin ES Ann Pharmacother; 1992 Nov; 26(11):1347-51. PubMed ID: 1362093 [TBL] [Abstract][Full Text] [Related]
8. Zidovudine-interferon-alpha combination therapy in patients with advanced human immunodeficiency virus type 1 infection: biphasic response of p24 antigen and quantitative polymerase chain reaction. Edlin BR; Weinstein RA; Whaling SM; Ou CY; Connolly PJ; Moore JL; Bitran JD J Infect Dis; 1992 May; 165(5):793-8. PubMed ID: 1349031 [TBL] [Abstract][Full Text] [Related]
9. 2',3'-didehydro-3'-deoxythymidine (d4T) in patients with AIDS or AIDS-related complex: a phase I trial. Browne MJ; Mayer KH; Chafee SB; Dudley MN; Posner MR; Steinberg SM; Graham KK; Geletko SM; Zinner SH; Denman SL J Infect Dis; 1993 Jan; 167(1):21-9. PubMed ID: 8093363 [TBL] [Abstract][Full Text] [Related]
10. Acute reactions associated with the infusion of ampligen. McMahon D; Winkelstein A; Huang XL; Armstrong J; Pazin G; Rinaldo C; Tripoli C; Ho M AIDS; 1992 Feb; 6(2):235-6. PubMed ID: 1558725 [No Abstract] [Full Text] [Related]
11. Effect of stage of disease and drug dose on zidovudine susceptibilities of isolates of human immunodeficiency virus. Richman DD; Grimes JM; Lagakos SW J Acquir Immune Defic Syndr (1988); 1990; 3(8):743-6. PubMed ID: 2114476 [TBL] [Abstract][Full Text] [Related]
12. In vivo activity against HIV and favorable toxicity profile of 2',3'-dideoxyinosine. Yarchoan R; Mitsuya H; Thomas RV; Pluda JM; Hartman NR; Perno CF; Marczyk KS; Allain JP; Johns DG; Broder S Science; 1989 Jul; 245(4916):412-5. PubMed ID: 2502840 [TBL] [Abstract][Full Text] [Related]
13. Reconstitution of long-term T helper cell function after zidovudine therapy in human immunodeficiency virus-infected patients. Clerici M; Landay AL; Kessler HA; Phair JP; Venzon DJ; Hendrix CW; Lucey DR; Shearer GM J Infect Dis; 1992 Oct; 166(4):723-30. PubMed ID: 1388195 [TBL] [Abstract][Full Text] [Related]
14. An hypothesis concerning optimal therapy in HIV disease. Gillespie D; Carter WA Med Hypotheses; 1992 Jan; 37(1):1-5. PubMed ID: 1569900 [TBL] [Abstract][Full Text] [Related]
15. Soluble tumor necrosis factor receptors as surrogate markers for the assessment of zidovudine treatment in asymptomatic HIV-1 infection. Godfried MH; van der Poll T; Mulder JW; Weverling GJ; Endert E; Lange JM; Sauerwein HP J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Dec; 10(5):531-9. PubMed ID: 8548332 [TBL] [Abstract][Full Text] [Related]
16. Antiviral activity of biological response modifiers in a murine model of AIDS. Requirement for augmentation of natural killer cell activity and synergy with oral AZT. Black PL; McKinnon KM; Wooden SL; Ussery MA Int J Immunopharmacol; 1996 Nov; 18(11):633-50. PubMed ID: 9089007 [TBL] [Abstract][Full Text] [Related]
17. Effects of glycyrrhizin (SNMC: Stronger Neo-Minophagen C) in hemophilia patients with HIV-1 infection. Mori K; Sakai H; Suzuki S; Akutsu Y; Ishikawa M; Imaizumi M; Tada K; Aihara M; Sawada Y; Yokoyama M Tohoku J Exp Med; 1990 Oct; 162(2):183-93. PubMed ID: 2129071 [TBL] [Abstract][Full Text] [Related]
18. Clinical, immunological, and virological effects of ampligen, a mismatched double-stranded RNA, in patients with AIDS or AIDS-related complex. Carter WA; Strayer DR; Brodsky I; Lewin M; Pellegrino MG; Einck L; Henriques HF; Simon GL; Parenti DM; Scheib RG Lancet; 1987 Jun; 1(8545):1286-92. PubMed ID: 2884413 [TBL] [Abstract][Full Text] [Related]
19. New "ThetaSwitch" drug may increase long-term survival in HIV disease. J Int Assoc Physicians AIDS Care; 1996 Apr; 2(4):59. PubMed ID: 11363523 [TBL] [Abstract][Full Text] [Related]
20. Changes in T-lymphocyte subpopulations during pregnancy complicated by human immunodeficiency virus infection. Dinsmoor MJ; Christmas JT Am J Obstet Gynecol; 1992 Dec; 167(6):1575-9. PubMed ID: 1471668 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]